What is MRD testing?

MRD testing, or Minimal Residual Disease testing, is a diagnostic technique used to detect small numbers of cancer cells that remain in the body after treatment — levels too low to be found with standard imaging or lab tests.

The U.S. Minimal Residual Disease (MRD) testing market is witnessing significant growth, driven by its vital role in cancer diagnostics and treatment monitoring, especially for hematologic malignancies like leukemia and lymphoma. By detecting traces of cancer cells that can persist after therapy, MRD testing provides vital information about patient prognosis and treatment choices. Modern oncology care now requires MRD testing because of its excellent sensitivity and accuracy. Its clinical value has been further increased by the use of cutting-edge technologies like digital PCR, flow cytometry, and Next-Generation Sequencing (NGS). MRD testing is currently available in many labs and medical facilities around the United States, highlighting its growing significance in individualized cancer treatment.

The U.S. MRD testing market was valued at $752.5 million in 2024 and is projected to reach $1,667.5 million by 2030, growing at a CAGR of 14.18% during the forecast period.

Which cancers are commonly monitored using MRD testing?

Hematologic (Blood) Cancers

• Acute Lymphoblastic Leukemia (ALL)

• Acute Myeloid Leukemia (AML)

• Chronic Lymphocytic Leukemia (CLL)

• Multiple Myeloma

• Non-Hodgkin’s Lymphoma

• Mantle Cell Lymphoma

Which companies or labs are leading in MRD testing services in the U.S.?

• Natera, Inc.

• Adaptive Biotechnologies

• Guardant Health

• Invitae Corporation (ArcherDX)

• NeoGenomics Laboratories

• Labcorp

• Mayo Clinic Laboratories
  

Objective of the Study

This study aims to systematically profile approximately 200 Minimal Residual Disease (MRD) Testing Facilities across the United States, encompassing the following categories:

• MRD Testing Laboratories 

• MRD Testing Hospitals 

• MRD Testing Companies 

• MRD Testing Centers 

• MRD Testing Volume 

• MRD Market 

The study is focused on profiling about 200 testing facilities in the U.S. providing valuable insights for strategic planning, market analysis, and benchmarking. Stakeholders can compare operational metrics, identify underserved regions, and explore partnership opportunities. The detailed test data helps optimize clinical workflows, adopt advanced technologies, and align with industry standards. It also supports compliance with regulatory requirements and enhances funding advocacy. Overall, the report is a comprehensive resource for driving innovation and competitiveness in the MRD testing landscape.

Gather more insights about the market drivers, restrains and growth of the U.S. MRD Testing Facilities Market! 

Learn more about Healthcare Vertical. Click Here!

Conclusion

The increasing adoption of these advanced technologies is revolutionizing MRD testing, making it more precise, accessible, and essential for shaping cancer treatment approaches. The need of creating individualized treatment programs based on the comprehensive genetic information gathered from MRD testing is increasing as the profession develops.

The market for MRD testing in the United States is leading the way in oncology diagnostics thanks to ongoing innovation, strategic partnerships, and a rising focus on customized medication. Although issues like sensitivity restrictions and cost obstacles still exist, developments in companion diagnostics, Medicare coverage extension, and clinical trials present encouraging answers. The market for MRD testing is positioned to improve patient outcomes and cancer care in the years to come by overcoming these obstacles and taking advantage of new opportunities.